Leerink Partnrs Forecasts Envista’s Q3 Earnings (NYSE:NVST)

Envista Holdings Co. (NYSE:NVST) – Investment analysts at Leerink Partnrs dropped their Q3 2025 earnings per share estimates for Envista in a report issued on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $0.26 per share for the quarter, down from their prior estimate of $0.30. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Envista’s current full-year earnings is $0.72 per share. Leerink Partnrs also issued estimates for Envista’s Q4 2025 earnings at $0.29 EPS, FY2025 earnings at $0.98 EPS and FY2026 earnings at $1.27 EPS.

A number of other equities analysts have also recently commented on NVST. Robert W. Baird lifted their price target on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, October 31st. Piper Sandler boosted their price objective on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday. Mizuho assumed coverage on Envista in a report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price objective for the company. Wells Fargo & Company boosted their price objective on Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Envista in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $20.21.

Envista Stock Performance

Envista stock opened at $21.76 on Friday. Envista has a 52 week low of $15.15 and a 52 week high of $24.79. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. The stock has a 50-day simple moving average of $19.97 and a 200 day simple moving average of $19.10.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NVST. Iron Triangle Partners LP bought a new position in shares of Envista in the third quarter valued at approximately $43,262,000. Point72 Asset Management L.P. bought a new position in shares of Envista in the third quarter valued at approximately $37,559,000. Polar Asset Management Partners Inc. lifted its holdings in shares of Envista by 375.6% in the third quarter. Polar Asset Management Partners Inc. now owns 1,497,250 shares of the company’s stock valued at $29,586,000 after purchasing an additional 1,182,450 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Envista by 26.5% during the third quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company’s stock valued at $78,480,000 after acquiring an additional 830,861 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC purchased a new stake in shares of Envista during the third quarter valued at approximately $14,965,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.